Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0LCUJ | ISIN: FR0010331421 | Ticker-Symbol: IDD
Tradegate
05.06.25 | 09:15
1,912 Euro
+0,21 % +0,004
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
INNATE PHARMA SA Chart 1 Jahr
5-Tage-Chart
INNATE PHARMA SA 5-Tage-Chart
RealtimeGeldBriefZeit
1,9101,92017:30
1,9121,91616:49

Aktuelle News zur INNATE PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
INNATE PHARMA Aktie jetzt für 0€ handeln
27.05.Innate Pharma SA - 6-K, Report of foreign issuer4
27.05.Innate Pharma SA: Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences428Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that members of its executive team will present and host 1x1 meetings at the upcoming...
► Artikel lesen
23.05.Innate Pharma SA: Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides341Long term follow-up data from the TELLOMAK Phase 2 trial in Sézary syndrome (SS) and mycosis fungoides (MF) will be presented at the ASCO Annual Meeting 2025. Long-term follow-up data from...
► Artikel lesen
23.05.Innate Pharma SA: Outcome of Innate Pharma's 2025 Annual General Meeting295Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") announced the voting results of its shareholders at the Annual General Meeting ("AGM"), which took...
► Artikel lesen
19.05.Innate Pharma SA - 6-K, Report of foreign issuer1
19.05.Innate Pharma SA: Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting241Long term follow-up results of TELLOMAK Phase 2 trial in Sézary syndrome and mycosis fungoides Trial in Progress poster on IPH4502, Innate's differentiated ADC in development in advanced...
► Artikel lesen
15.05.Innate Pharma SA: Innate Pharma Highlights ANKET Abstracts Selected for the EHA 2025 Congress285Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that an abstract regarding IPH6501, its ANKET targeting CD20 B cells currently...
► Artikel lesen
13.05.Innate Pharma S.A. reports Q1 results2
13.05.Innate Pharma Q1 2025 slides: pipeline advances and Sanofi partnership strengthen outlook22
13.05.Innate Pharma Q1 Revenue Declines, Stock Down2
13.05.Innate Pharma reports Q1 results1
13.05.Innate Pharma SA: Innate Pharma Reports First Quarter 2025 Business Update and Financial Results395€15 million investment by Sanofi, in addition to the ongoing partnership including the development of BCMA targeting ANKET program in autoimmune indications First patient dosed in a Phase...
► Artikel lesen
12.05.Innate Pharma SA - 6-K, Report of foreign issuer1
12.05.Innate Pharma SA: Number of Shares and Voting Rights of Innate Pharma as of May 5, 2025209Regulatory News: Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General...
► Artikel lesen
06.05.Innate Pharma SA: Innate Pharma announces conference call and webcast for Q1 2025 business update219Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announced that the Company will hold a conference call on Tuesday, May 13, 2025, at 2 p.m....
► Artikel lesen
30.04.Innate Pharma SA: Innate Pharma Files Its 2024 Universal Registration Document (Document d'enregistrement universel) and 2024 Annual Report on Form 20-F218Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced the filing of its 2024 Universal Registration Document (Document d'enregistrement...
► Artikel lesen
30.04.Innate Pharma SA - 6-K, Report of foreign issuer1
30.04.Innate Pharma SA - 20-F, Annual and transition report of foreign private issuers1
29.04.Innate Pharma stock surges on promising preclinical data2
29.04.Innate Pharma-Aktie steigt nach vielversprechenden präklinischen Daten2
Weiter >>
81 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1